ArticleJournal of virology2015
Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses.
Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- CrossDome: an interactive R package to predict cross-reactivity risk using immunopeptidomics databases.Frontiers in immunology · 2023Article
- Article
- SARS-Arena: Sequence and Structure-Guided Selection of Conserved Peptides from SARS-related Coronaviruses for Novel Vaccine Development.Frontiers in immunology · 2022Article
- Mechanistic diversity in MHC class I antigen recognition.The Biochemical journal · 2021Review
- Expansion of Unique Hepatitis C Virus-Specific Public CD8Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Virus-Induced T Cell-Mediated Heterologous Immunity and Vaccine Development.Frontiers in immunology · 2020Review
- Article
- Heterologous Immunity: Role in Natural and Vaccine-Induced Resistance to Infections.Frontiers in immunology · 2019Review
- General Prediction of Peptide-MHC Binding Modes Using Incremental Docking: A Proof of Concept.Scientific reports · 2018Article
- T cell phenotypes in women with Chlamydia trachomatis infection and influence of treatment on phenotype distributions.Microbes and infection · 2018Article
- An AdaptiveFrontiers in immunology · 2018Article
- Respiratory virus-induced heterologous immunity: Part of the problem or part of the solution?Allergo journal international · 2018Review
- Respiratory virus-induced heterologous immunity: Part of the problem or part of the solution?Allergo Journal : interdisziplinare Zeitschrift fur Allergologie und Umweltmedizin : Organ der Deutschen Gesellschaft fur Allergie- und Immunitatsforschung · 2018Review
- Article
- Distinct peripheral vs mucosal T-cell phenotypes in chlamydia-infected women.American journal of reproductive immunology (New York, N.Y. : 1989) · 2017Article
- Unsolved Puzzles Surrounding HCV Immunity: Heterologous Immunity Adds Another Dimension.International journal of molecular sciences · 2017Review
- The Predominant CD4Clinical and vaccine immunology : CVI · 2017Article
- Selective expansion of high functional avidity memory CD8 T cell clonotypes during hepatitis C virus reinfection and clearance.PLoS pathogens · 2017Article
- T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV.Antiviral research · 2017Review
- Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy.Frontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledT cell responses play a critical role in controlling or clearing viruses. Therefore, strategies to prevent or treat infections include boosting T cell responses. T cells specific for various pathogens have been reported in unexposed individuals and an influence of such cells on the response toward vaccines is conceivable. However, little is known about their frequency, repertoire, and impact on vaccination. We performed a detailed characterization of CD8(+) T cells specific to a hepatitis C virus (HCV) epitope (NS3-1073) in 121 HCV-seronegative individuals. We show that in vitro HCV NS3-1073-specific CD8(+) T cell responses were rather abundantly detectable in one-third of HCV-seronegative individuals irrespective of risk factors for HCV exposure. Ex vivo, these NS3-1073-specific CD8(+) T cells were found to be both naive and memory cells. Importantly, recognition of various peptides derived from unrelated viruses by NS3-1073-specific CD8(+) T cells showed a considerable degree of T cell cross-reactivity, suggesting that they might in part originate from previous heterologous infections. Finally, we further provide evidence that preexisting NS3-1073-specific CD8(+) T cells can impact the T cell response toward peptide vaccination. Healthy, vaccinated individuals who showed an in vitro response toward NS3-1073 already before vaccination displayed a more vigorous and earlier response toward the vaccine. IMPORTANCE: Preventive and therapeutic vaccines are being developed for many viral infections and often aim on inducing T cell responses. Despite effective antiviral drugs against HCV, there is still a need for a preventive vaccine. However, the responses to vaccines can be highly variable among different individuals. Preexisting T cells in unexposed individuals could be one reason that helps to explain the variable T cell responses to vaccines. Based on our findings, we suggest that HCV CD8(+) T cells are abundant in HCV-seronegative individuals but that their repertoire is highly diverse due to the involvement of both naive precursors and cross-reactive memory cells of different specificities, which can influence the response to vaccines. The data may emphasize the need to personalize immune-based therapies based on the individual's T cell repertoire that is present before the immune intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.